Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

<br><strong>Background </strong>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. <br><strong> Methods </...

Detaylı Bibliyografya
Asıl Yazarlar:	de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2021

Benzer Materyaller

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
Yazar:: de Vlam, K, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
Yazar:: de Vlam, K, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
Yazar:: Taylor, P, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
Yazar:: Taylor, PC, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
Yazar:: Dougados, M, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Yazar:: Iain B McInnes, ve diğerleri
Baskı/Yayın Bilgisi: (2020-02-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Yazar:: Dougados, M, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Yazar:: Maxime Dougados, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Yazar:: Gladman, DD, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
Yazar:: Taylor, PC, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
Yazar:: Kristensen, LE, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Yazar:: Philip J. Mease, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Yazar:: Taylor, P, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
Yazar:: Daniela Graham, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Yazar:: Dafna D. Gladman, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Yazar:: Laura C. Coates, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Yazar:: Peter C. Taylor, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Measuring outcomes in psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Yazar:: Alexis Ogdie, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
Yazar:: Lars Erik Kristensen, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Psoriatic arthritis
Yazar:: FitzGerald, O, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
Yazar:: Victoria Navarro-Compán, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
Yazar:: Marta Skorupska, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
Yazar:: Taylor, PC, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Yazar:: Philip J Mease, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
Yazar:: Philip J Mease, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
Yazar:: Taylor, P, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Yazar:: Kevin L. Winthrop, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Yazar:: Lars E. Kristensen, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
Yazar:: Burmester, GR, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Yazar:: Ly K, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Yazar:: Gerd R. Burmester, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Yazar:: Peter Nash, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
Yazar:: Leung, Y, ve diğerleri
Baskı/Yayın Bilgisi: (2018)